AACR 2022 poster. Using solid tumor analytical validation of T-regulatory immunohistochemistry multiplex for clinical studies
Our Histoprofile®- T-reg light panel is ready for use in your clinical trials
Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues. Evaluate T-cell subpopulations and their spatial distribution in the tumor microenvironment.
CerbACT Asia – Center of Excellence in Immuno-Oncology
CerbACT Asia empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research & clinical development strategies, combining the strengths of Cerba Research and ACT Genomics. We are enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC/cell isolations, while functioning as a central laboratory in the APAC region. Working with biotech, pharma, government and nongovernmental organizations, our team is ready to turn precision medicine into action!
Download the flyer to learn more on CerbACT Asia’s capabilities.
Precision Medicine in Practice for Non-Small Cell Lung Cancer (NSCLC)
At the 16th Biomarkers UK Congress in November 2021, Rania Gaspo, PhD gave a talk on implementing precision medicine for Non-Small Cell Lung Cancer. How can you bring precision medicine into practice? What roles can Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and ctDNA play?
Webinar: Turning Precision Medicine into Action in Immuno-Oncology
The challenges in immuno-oncology (I/O) drug development require deep scientific insights, generation and analysis of complex biological data, new state-of-the art technologies and both logistical & operational support across continents. The goal of immuno-oncology drug developers is to turn precision medicine into action, bringing life-changing therapies to patients.
In this webinar originally held on October 4 our experts discuss the use of Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Flow Cytometry (FCM) within immuno-oncology, and how they can offer the comprehensive insights required for I/O clinical trials.
- Jérôme Sallette, PhD, CSO Cerba Research
- Shu Jen Chen, PhD, CSO ACT Genomics
- Sofie Vandevyver, PhD, Head of Business Operations & Marketing Cerba Research
- George Wei, PhD, Vice President R&D ACT Genomics
- Renaud Burrer, PhD, Head of Histopathology Cerba Research
- Nithianandan Selliah, PhD, Global Head Flow Cytometry Cerba Research
Submit your information below to watch the webinar or to download the slide deck to receive our expert’s insights.
Immunohistochemistry (IHC): Increase the Success of Biomarker Integration in Clinical Development
“With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, you can increase the success of biomarker integration in clinical development.”
– Amanda Finan, PhD, Head IHC/Histology R&D and Clinical Validations at Cerba Research
HISTOSELECT: How to Overcome Challenges in Antibody Selection?
HISTOSELECT®: The number one solution for direct screening of large numbers of antibodies by immunohistochemistry (IHC).
The Complexity of Myeloid-Derived Suppressor Cells in Non-small Cell Lung Cancer: A Combinatorial Multiplex IHC and Flow Cytometry Approach
A Biomarker Journey in Immuno-Oncology Utilizing Immunohistochemistry
In immuno-oncology (IO) research, biomarkers present the opportunity to identify and target the patient response to a potential new therapeutic, but how can it be integrated into a clinical development plan to increase the effectiveness of clinical trials?
With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, sponsors will increase the success of biomarker integration in their clinical trials.
Watch our webinar now!
A Single Picture Does Not Say It All: A Case for Comprehensive Biomarker Use in Cancer Research
During the Virtual Biomarkers Congress Eitan Akirav presented A Single Picture Does Not Say It All, a case for comprehensive biomarker use within oncology research. Did you miss out on his presentation during the conference? Now you can submit the form below to watch it at your own leisure!
Biomarkers in Immuno-Oncology: Identifying and Implementing Biomarker Testing from Exploratory Research to Clinical Trials
Biomarkers are at the heart of Immuno-Oncology. In this webinar, we will walk you through three case studies to highlight the importance of biomarkers, using different methodologies. Why do some patients respond better to I/O therapeutics than others? What is Flow Cytometry’s role in immunophenotyping? Where does Immunohistochemistry come in? What is the Tumor Mutation Burden, how does it impact I/O research?
Amanda Finan, Head of IHC R&D Cerba Research, Nithianandan Selliah, Global Head of Flow Cytometry Cerba Research, and Raouf Ben Abdelali, Head of the Hematology and Oncology Division, Cerba Laboratory will guide you through their respective fields of expertise and answer the above questions.